These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 37940142

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: a systematic review and meta-analysis.
    Mbinta JF, Nguyen BP, Awuni PMA, Paynter J, Simpson CR.
    Lancet Healthy Longev; 2022 Apr; 3(4):e263-e275. PubMed ID: 36098300
    [Abstract] [Full Text] [Related]

  • 3. Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention.
    Klein NP, Bartlett J, Fireman B, Marks MA, Hansen J, Lewis E, Aukes L, Saddier P.
    Vaccine; 2019 Aug 23; 37(36):5422-5427. PubMed ID: 31301920
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study.
    Amirthalingam G, Andrews N, Keel P, Mullett D, Correa A, de Lusignan S, Ramsay M.
    Lancet Public Health; 2018 Feb 23; 3(2):e82-e90. PubMed ID: 29276017
    [Abstract] [Full Text] [Related]

  • 5. A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan.
    Yaegashi M, Matsui H, Yoshida A, Ban H, Miyazaki R, Oda N, Hattori K, Motomura Y, Usami H, Matsushita H.
    Vaccine; 2024 Jan 25; 42(3):464-470. PubMed ID: 38172019
    [Abstract] [Full Text] [Related]

  • 6. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study.
    Langan SM, Smeeth L, Margolis DJ, Thomas SL.
    PLoS Med; 2013 Jan 25; 10(4):e1001420. PubMed ID: 23585738
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of herpes zoster vaccination in an older United Kingdom population.
    Walker JL, Andrews NJ, Amirthalingam G, Forbes H, Langan SM, Thomas SL.
    Vaccine; 2018 Apr 19; 36(17):2371-2377. PubMed ID: 29555217
    [Abstract] [Full Text] [Related]

  • 8. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
    Tseng HF, Lewin B, Hales CM, Sy LS, Harpaz R, Bialek S, Luo Y, Jacobsen SJ, Reddy K, Huang PY, Zhang J, Anand S, Bauer EM, Chang J, Tartof SY.
    J Infect Dis; 2015 Oct 15; 212(8):1222-31. PubMed ID: 26038400
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Hornberger J, Robertus K.
    Ann Intern Med; 2006 Sep 05; 145(5):317-25. PubMed ID: 16954357
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM, Brisson M, Levin MJ.
    Vaccine; 2007 Nov 28; 25(49):8326-37. PubMed ID: 17980938
    [Abstract] [Full Text] [Related]

  • 11. Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study.
    Baxter R, Bartlett J, Fireman B, Marks M, Hansen J, Lewis E, Aukes L, Chen Y, Klein NP, Saddier P.
    Am J Epidemiol; 2018 Jan 01; 187(1):161-169. PubMed ID: 29309521
    [Abstract] [Full Text] [Related]

  • 12. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults.
    Sanford M, Keating GM.
    Drugs Aging; 2010 Feb 01; 27(2):159-76. PubMed ID: 20104941
    [Abstract] [Full Text] [Related]

  • 13. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany.
    Curran D, Van Oorschot D, Matthews S, Hain J, Salem AE, Schwarz M.
    Hum Vaccin Immunother; 2021 Dec 02; 17(12):5296-5303. PubMed ID: 34905463
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Rothberg MB, Virapongse A, Smith KJ.
    Clin Infect Dis; 2007 May 15; 44(10):1280-8. PubMed ID: 17443464
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study.
    Drolet M, Zhou Z, Sauvageau C, DeWals P, Gilca V, Amini R, Bénard É, Brisson M.
    CMAJ; 2019 Aug 26; 191(34):E932-E939. PubMed ID: 31451524
    [Abstract] [Full Text] [Related]

  • 16. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status.
    Marin M, Yawn BP, Hales CM, Wollan PC, Bialek SR, Zhang J, Kurland MJ, Harpaz R.
    Hum Vaccin Immunother; 2015 Aug 26; 11(5):1157-64. PubMed ID: 25806911
    [Abstract] [Full Text] [Related]

  • 17. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.
    Brisson M, Pellissier JM, Camden S, Quach C, De Wals P.
    Hum Vaccin; 2008 Aug 26; 4(3):238-45. PubMed ID: 18382137
    [Abstract] [Full Text] [Related]

  • 18. Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia.
    Betts RF.
    J Am Acad Dermatol; 2007 Dec 26; 57(6 Suppl):S143-7. PubMed ID: 18021866
    [Abstract] [Full Text] [Related]

  • 19. Public health impact of herpes zoster vaccination on older adults in Hong Kong.
    Chan PKS, Wong MCS, Chan M, Ching K, Giannelos N, Ng C.
    Hum Vaccin Immunother; 2023 Dec 31; 19(1):2176065. PubMed ID: 36854447
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States.
    Lu A, Sun Y, Porco TC, Arnold BF, Acharya NR.
    Ophthalmology; 2021 Dec 31; 128(12):1699-1707. PubMed ID: 33892049
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.